Combined ratio improved to 90.1% but solvency fell from 271% to 205%

The combined ratio improved to 90.1% from 91.4%, and underwriting profit rose to $35.7m from $28.7m, on a lower claims ratio excluding large events (48.9% versus 50.2%) and a lower expense ratio (36.0% versus 37.0%). Solvency, however, fell from 271% to 205%, and cash and equivalents dropped to $84.5m from $116.1m.

Revenue rose to $441.5m from $395.5m (the canonical revenue growth rate carries a basis-discontinuity flag, so we describe it qualitatively only). Profit before tax declined to $25.2m from $28.5m, while NPAT moved from $18.7m to $18.8m; this NPAT comparison carries a basis-discontinuity quality flag and is not a clean like-for-like trend, partly because the current period includes a discontinued operation contribution while the prior did not, and because a lower effective tax rate of 30.1% (versus 32.1%) flattered the after-tax line. Operating cash inflow fell to $59.8m from $98.6m. The final dividend was 4.0 cents (versus 2.5 cents); full-year dividend 6.5 cents (versus 5.0 cents).

Underwriting strengthened, which is the core insurance read. A 90.1% combined ratio means each premium dollar generated about 9.9 cents of underwriting profit. Claims and expense ratios both improved, suggesting the gain is structural rather than one-off, although the large-event claims ratio rose to 5.3% (from 4.2%) and $22m of reinsurance recoveries under the aggregate cover supported the reported result.

2. The capital position weakened materially. The 66 percentage-point drop in solvency to 205% reflects in part capital management (higher dividend, value-accretive acquisitions) but it is the principal counterweight to the underwriting story and reduces the buffer against future catastrophe years.

3. Cash conversion deteriorated. Operating cash inflow fell about $38.9m while reported NPAT was essentially level (a comparison whose growth rate is basis-discontinuity flagged and not analytically comparable as a clean trend), and pre-lease free cash flow of $56.6m sits well below Annolyse's historical baseline mean of $97.1m. The headline NPAT obscures this pressure, and the larger dividend is being funded against a weaker cash baseline.

First-half NPAT of $2.9m represented just 15.6% of the full-year figure, so the second half delivered roughly $15.9m. That skew reflects large-event timing, aggregate reinsurance treaty mechanics and the inflation/claims pressure flagged at HY22; the result is heavily back-half weighted rather than evenly produced.

Against the company's historical baseline, the NPAT margin of 4.3% and total assets of $904.2m sit inside the supplied historical range, though both growth and return metrics carry basis-discontinuity caveats that make year-on-year trend framing not analytically comparable. The result supports a read of FY22 as a rebuild year on combined ratio rather than a step-change on earnings power.

Lower claims and expense ratios reflect mix and pricing discipline, and the investment result improved modestly to $1.2m from $0.2m. Two items qualify that durability: $22m of reinsurance recoveries under the FY22 aggregate cover supported the reported claims line, and the lower effective tax rate of 30.1% versus 32.1%, together with a $1.2m after-tax contribution from a discontinued operation, means the NPAT comparison is basis-distorted rather than a clean operating read. Profit from continuing operations was $17.6m, so the underlying operating profile is softer than the headline NPAT suggests.

The cash side is weaker. OCF fell to $59.8m from $98.6m on a reported earnings comparison that is basis-discontinuity flagged, and the cash balance dropped $31.6m. Pre-lease FCF/NPAT of 301.2% looks elevated in isolation, but the FCF dollars themselves are well below the historical baseline, and dividends plus capital management drew further on the balance sheet (solvency 205% versus 271%). The dividend is affordable from the cash base, but cash quality has weakened rather than supported the higher distribution.

This briefing cannot assess Tower's FY23 reinsurance treaty pricing or the underlying claims-inflation trajectory beyond what the FY22 disclosures directly reveal.